捷迈邦美 2024年度报告

Financial Highlights* 2024 Sales by Geography Net Sales Operating Profit Operating Cash Flow Diluted Earnings per Share The decrease in cash flow fromoperating activities in 2024 from2023 was primarily due to ahigher volume of accountspayments near the end of 2024relative to 2023 as well as higherbonus, income tax andrestructuring-related payments. Our 2024 reported operatingprofit was relatively consistentwith 2023. Higher net sales andlower research and developmentexpense were offset by higherrestructuring charges andintangible asset amortization.Our 2024 adjusted operatingprofit improved from 2023primarily due to higher net salesand cost reduction initiatives. Zimmer Biomet recorded netsales of $7.679 billion in 2024,an increase of 3.8% comparedto 2023 primarily due acombination of market growth,new product introductions,positive price realization andcommercial execution across theorganization, partially offset byoperational challenges we faceddue to an ERP implementationwhich impacted our ability tofulfill certain customer orders. Reported diluted earnings pershare decreased in 2024 primarilydue to higher restructuringexpense in 2024 as well as higherfavorable tax settlements in 2023compared to 2024. Adjusteddiluted earnings per shareimproved in 2024 primarily due tohigher net sales and cost reductioninitiatives. To Our Shareholders, In 2024, Zimmer Biomet transformed the lives of more than 4 million patients worldwide. We also took proactive steps designed to continue to drive long-term, sustainable growth amidst a complex andevolving healthcare landscape. Building on our strong foundation, we made notable progress in advancing our StrategicPriorities, delivering meaningful financial results for our shareholders and bringing important new products to marketwhile seizing new opportunities along the way. Our journey to being the boldest company in MedTech is ongoing, and we remained focused on disciplined execution,innovation and operational excellence. Our Three Strategic Priorities We remain committed to three key priorities that continue to shape our business, and we made meaningful progress ineach of these areas throughout the year: •People & Culture –Fostering an environment where top talent thrives and innovation flourishes.•Operational Excellence –Enhancing efficiency, agility and continuous improvement across our organization.•Innovation & Diversification –Expanding our portfolio and capabilities to meet the evolving needs of patients andhealthcare providers worldwide. 2024 Highlights People & Culture •Expanded global recognition as a Great Place to Work®, earning and retaining certifications in multiple countries.•Strengthened our Environmental, Social and Governance efforts, achieving top-tier sustainability ratings andpublishing our latest Sustainability Report.•Advanced health equity through key partnerships, including a collaboration with RevelAI to commercialize AI-powered engagement solutions that enhance value-based orthopedic care. Operational Excellence •Successfully completed a global restructuring program, yielding significant efficiency gains and cost savings. •Returned capital to shareholders through continued share buybacks and disciplined capital allocation.•Enhanced operating mechanisms, including refocusing our research and development programs to furtherprioritize innovation, which we believe positions us for improved growth. Innovation & Diversification •Delivered meaningful innovation to Reconstructive surgery, reinforcing our leadership in musculoskeletalhealthcare, including:oPersona®OsseoTi®Cementless Knee, Persona®Revision Knee receiving the CE Mark, and Oxford®CementlessPartial Knee becoming the only FDA-approved cementless partial knee in the U.S.oROSA®Shoulder, receiving FDA clearance in early 2024, and the introduction of the OsseoFit™StemlessShoulder System. •Introduced key advancements in our robotics and digital health ecosystem, including new developments withinZBEdge®Dynamic Intelligence™Platform and mymobility®with Apple Watch®.1•Strengthened our market position through strategic acquisitions, including:oVIMS, enhancing our Sports Medicine and arthroscopy offerings.oOrthoGrid Systems, Inc., reinforcing our commitment to AI-driven surgical guidance systems.oSaphena Medical, Inc., accelerating growth in our cardiac business with next-generation vein harvesting solutions.•Established an exclusive partnership with CBRE Group, Inc., the world's largest commercial real estate services andinvestment firm, to grow the ambulatory surgery center footprint in the U.S.•Negotiated and, in January 2025, entered into a definitive agreement to acquire Paragon 28, Inc., a leading foot andankle medical device company which, upon closing, will expand our reach into a high-growth orthopedic segment. In addition, we underscored our commitment to movement and health in 2024 as we welcomed Arnold Schwarzeneggeras our Chief Movement Officer and became the offi